EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 347 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal September 1, 2022 Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical... December 20, 2022 Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... October 14, 2025 Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response July 15, 2022 Load more HOT NEWS New on NCI’s Websites for August 2024 Thank you! Targeted prostate cancer screening: Are we there yet? Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why...
